FDA Oncology Announcements

Announcements Trials

Anti-RANKL × Genitourinary × Clear all

Conditions

Breast 1 Genitourinary 1 Plasma cell 1 Sarcoma 1

Drug Classes

Anti-PD-1 19 VEGFR inhibitor 12 Second-generation nonsteroidal antiandrogen 10 Anti-PD-L1 9 PARP inhibitor 7 Anti-nectin-4 ADC 5 Alkylating agent 3 CYP17 inhibitor 3 GnRH antagonist 3 MTOR inhibitor 3 Pyrimidine analog 3 Taxane 3 FGFR inhibitor 2 HIF-2a inhibitor 2 Multi-ingredient 2 Multikinase inhibitor 2 Platinum agent 2 Radioactive agent 2 TRK inhibitor 2 Adenovirus vector 1 Anti-CTLA-4 1 Anti-HER2 ADC 1 Anti-RANKL 1 Anti-TACSTD2 ADC 1 Anti-VEGFR 1 BRAF inhibitor 1 IL-15 receptor alpha fusion protein 1 MEK inhibitor 1 RET inhibitor 1 ROS1 inhibitor 1

1 Announcement

Denosumab (Prolia)

Drug: Prolia (denosumab) · Anti-RANKL antibody
Conditions: BreastGenitourinary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡